Severe phenytoin intoxication in a subject homozygous for CYP2C9*3

被引:83
作者
Brandolese, R
Scordo, MG
Spina, E
Gusella, M
Padrini, R
机构
[1] Univ Padua, Dept Pharmacol & Anesthesiol, I-35131 Padua, Italy
[2] Univ Messina, Inst Pharmacol, Messina, Italy
[3] Conselve Hosp, Rehabil Serv, Padua, Italy
关键词
D O I
10.1067/mcp.2001.118868
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A 31-year-old woman who had a severe head injury was treated with oral phenytoin (100 mg 3 times a day) to prevent posttraumatic seizures. On day 10 of phenytoin treatment, 3 hours after the morning dose, the patient manifested neurologic signs compatible with phenytoin intoxication. Thus drug serum concentrations were monitored daily for 12 days. The elimination half-life was 103 hours, namely, about 5 times longer than the mean value generally quoted (22 hours). In the absence of any acquired predisposing factor for phenytoin toxicity, genetic mutations in the cytochrome P450 (CY-P) enzymes responsible for phenytoin metabolism (CYP2C9 and CYP2C19) were suspected. Genotyping revealed that the patient was homozygous for the C gamma P2C9*3 allele (C gamma P2C9*3/*3) and heterozygous for the C gamma P2C19*2 allele (C gamma P2C19*1/*2). In view of the markedly reduced metabolic activity of C gamma P2C*3 in comparison with the wild-type enzyme (about one fifth) and of the minor role of C gamma P2C19 in phenytoin metabolism, it is likely that C gamma P2C9*3 mutation was largely responsible for drug overdose.
引用
收藏
页码:391 / 394
页数:4
相关论文
共 16 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]  
Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
[3]  
DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
[4]  
DOLLERY C, 1999, THERAPEUTIC DRUGS, P110
[5]   PHENYTOIN - PHARMACOGENETIC POLYMORPHISM OF 4'-HYDROXYLATION [J].
INABA, T .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) :341-347
[6]   Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele [J].
Kidd, RS ;
Straughn, AB ;
Meyer, MC ;
Blaisdell, J ;
Goldstein, JA ;
Dalton, JT .
PHARMACOGENETICS, 1999, 9 (01) :71-80
[7]   The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics [J].
Mamiya, K ;
Ieiri, I ;
Shimamoto, J ;
Yukawa, E ;
Imai, J ;
Ninomiya, H ;
Yamada, H ;
Otsubo, K ;
Higuchi, S ;
Tashiro, N .
EPILEPSIA, 1998, 39 (12) :1317-1323
[8]   Cytochrome P4502C9: an enzyme of major importance in human drug metabolism [J].
Miners, JO ;
Birkett, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (06) :525-538
[9]   Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication [J].
Ninomiya, H ;
Mamiya, K ;
Matsuo, S ;
Ieiri, I ;
Higuchi, S ;
Tashiro, N .
THERAPEUTIC DRUG MONITORING, 2000, 22 (02) :230-232
[10]   Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy [J].
Odani, A ;
Hashimoto, Y ;
Otsuki, Y ;
Uwai, Y ;
Hattori, H ;
Furusho, K ;
Inui, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (03) :287-292